Health: Cancer Fighter

A study shows letrozole helps breast-cancer survivors remain disease-free

For postmenopausal women who have been treated for breast cancer, five is a magic number. The standard therapy for tackling the majority of their tumors is surgery to remove the lumps, then the drug tamoxifen for five years to prevent cancer from recurring. After five years, the body becomes resistant to tamoxifen's effects. At that point, women stop taking it, cross their fingers and hope for the best. "There wasn't really anything available for them," explains Dr. Andrew von Eschenbach, director of the National Cancer Institute. "Yet we knew that many women risk recurrences even beyond five years."

Last week researchers...

Want the full story?

Subscribe Now

Subscribe
Subscribe

Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!